FDA grants AP status for Glyburide and Metformin Hydrochloride by Impax
The FDA has granted Abbreviated Approval (AP) status for Glyburide and Metformin Hydrochloride submitted by Impax under application ANDA076345.
Asset / Drug
Drug and asset intelligence for Impax with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.